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Alzheimer’s disease (AD) risk genes alter brain structure and function decades before
disease onset. Apolipoprotein E (APOE) is the strongest known genetic risk factor for AD,
and a related gene, apolipoprotein J (APOJ), also affects disease risk. However, the extent
to which these genes affect brain structure in young adults remains unclear. Here, we
report that AD risk alleles of these two genes, APOE-ε4 and APOJ-C, cumulatively alter
brain volume in young adults. Using voxel-based morphometry (VBM) in 57 individuals,
we examined the entorhinal cortex, one of the earliest brain regions affected in AD
pathogenesis. Apolipoprotein E-ε4 carriers exhibited higher right entorhinal cortex volume
compared to non-carriers. Interestingly, APOJ-C risk genotype was associated with higher
bilateral entorhinal cortex volume in non-APOE-ε4 carriers. To determine the combined
disease risk of APOE and APOJ status per subject, we used cumulative odds ratios as
regressors for volumetric measurements. Higher disease risk corresponded to greater
right entorhinal cortex volume. These results suggest that, years before disease onset,
two key AD genetic risk factors may exert influence on the structure of a brain region
where AD pathogenesis takes root.
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INTRODUCTION
Multiple genetic polymorphisms have been shown to increase
Alzheimer’s disease (AD) risk without guaranteeing its onset
(Bertram et al., 2007). Though the mechanisms of genetic risk
are largely unknown, one possibility is that risk gene-dependent
vulnerabilities and age-dependent vulnerabilities may interact to
trigger neurodegeneration (Risacher et al., 2010; Reinvang et al.,
2013). Genome-wide association studies have repeatedly shown
that the ε4 allele of the apolipoprotein E (APOE) gene is the
strongest known genetic risk factor for AD, increasing risk by
200–300% and decreasing age of onset, in a dose-dependent
manner (Farrer et al., 1997; Bertram et al., 2007; Harold et al.,
2009; Fei and Jianhua, 2013). A related risk factor, apolipopro-
tein J (APOJ, also known as clusterin, CLU), also modestly
increases AD risk, with the APOJ-C risk allele increasing AD
risk by 10–15% (Harold et al., 2009; Lambert et al., 2009).
These two AD risk genes encode similar proteins that associate
with lipoproteins in the brain (Koch et al., 2001; Elliott et al.,
2010) to interact with a shared family of cell surface receptors
(Kounnas et al., 1995; Leeb et al., 2014) that promote neurite
outgrowth (Nathan et al., 1994; Kang et al., 2005), cholesterol
metabolism (for review, see Holtzman et al., 2012), and clearance
of the AD pathological hallmark, amyloid-β (Demattos et al.,
2004).
Apolipoprotein E genotype is associated with accelerated
atrophy in the brain during disease progression (Shen et al., 2010),
and the gray matter density in the medial temporal lobe (MTL) of
APOE-ε4 carriers is particularly sensitive to this type of atrophy
(Thomann et al., 2008; Fei and Jianhua, 2013). While the effect
of APOE genotype on MTL atrophy has been well established in
older adults, effects on the young brain are less clear. Whole brain
analyses in healthy APOE-ε4 carriers report increased (Alexander
et al., 2012), decreased (Wishart et al., 2006; O’dwyer et al., 2012;
Knickmeyer et al., 2013), or unchanged (Mondadori et al., 2007;
Filippini et al., 2009; Dennis et al., 2010; Samuraki et al., 2012;
Stein et al., 2012; Matura et al., 2014) MTL volume depending
on the experimental parameters. Although less studied than
APOE-ε4, APOJ was also not associated with MTL differences
in a large scale genome-wide association study (GWAS) meta-
analysis (Stein et al., 2012). As with APOE, it may be that more
sensitive analyses are necessary to detect differences induced by
APOJ risk. Thus, our aim was to assay gray matter volume in a
particular area of the MTL that is susceptible to AD pathology
very early in the disease, the entorhinal cortex (Braak et al.,
2011). The entorhinal cortex facilitates communication between
the hippocampus and neocortex for memory consolidation.
We sought to test whether APOE and APOJ genotypes affected
entorhinal cortex volume in a cohort of young adults. In addition,
the putative functional similarities between the proteins these
genes encode (Kounnas et al., 1995; Koch et al., 2001; Elliott et al.,
2010; Leeb et al., 2014) prompted us to explore whether APOE
and APOJ polymorphisms may have a cumulative effect, which
would suggest the potential of a common pathway for these risk
factors in a region critical for AD pathogenesis.
Frontiers in Human Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 779 | 1
DiBattista et al. AD risk and entorhinal cortex volume
MATERIALS AND METHODS
PARTICIPANTS
Participants were healthy, right-handed university students and
community members (n = 57, 33 male, 74% Caucasian). Each
participant provided informed consent for MRI and genotyping.
These participants ranged from 18–35 years of age (mean =
21.8, standard deviation = 4.0) with no history of mental illness,
psychoactive medication or brain injury. All procedures received
IRB approval prior to the study.
GENOTYPING
We performed genotyping of the human APOJ (or CLU)
polymorphism at rs11136000, human APOE polymorphism
at rs429358 (codon 112), and human APOE polymorphism at
rs7412 (codon 158) using the TaqMan assay (Applied Biosystems).
A reaction volume of 25 µL containing 50 ng DNA, 5 mL MgCl2
and 1X TaqMan Universal PCR Master Mix containing AmpliTaq
Gold DNA Polymerase was amplified using 40 cycles of 15 s at
95◦C and 1 min at 60◦C. A total of 0.2µM of each of the sequence-
specific probes 5′-6FAM ACCAAAGCCACACCAGCTATCAAA
A[T]TCT CTAACGGGCCCTTGCCACTTGA-TAMRA-3′ and 5′-
VIC-ACCAAAGCCA CACCAGCTATCAAAA[C]TCTCTAACGG
GCCC TTGCCACTTGA-TAMRA-3′ were used in the allelic
discrimination assay for APOJ. For the allelic discrimination
assay for APOE, sequence specific probes were also used: 5′ VIC-
CCGCGATGCCGATGACCTGCAGAAG [C]GCCTGGCAGTGT
ACCAGGCCGGGGC–TAMRA-3′ and 5′FAM-CCGCGATGCC G
ATGACCTGCAGAAG[T]GCCTGGCAGT GTACCAGGCCGGG
GC-TAMRA-3′ for rs7412 and 5′ VIC-GCTGGGCGCG GACATG
GAGGACGTG[C]GCGGCCGCCTGGTGCAGTACCGCGG-TA
MRA-3′ and 5′FAM-GCTGGGCGCGGACATGGAGGACGTG[T]
GCGGCCGCCTGGT GCAGTACCGCGG-TAMRA-3′ for rs429
358. Allele detection and genotype calling were performed
using the ABI 7700 and Sequence Detection Software (Applied
Biosystems). All calls scored at least 95% quality values and were
verified by 100% recall on ∼20% of samples that were re-tested
for quality control.
IMAGE ACQUISITION, PROCESSING, AND ANALYSIS
Magnetic resonance imaging images were acquired using a 3-
T Allegra System (Siemens, Erlangen, Germany). Whole-brain
structural T1-weighted magnetization-prepared rapid gradient-
echo (MPRAGE) images were acquired for each subject (FOV
= 256 mm; 256 × 256 matrix; 1 × 1 mm in-plane resolution,
1.25 mm thick axial slices, 1 average). All MPRAGE images were
processed using SPM81 on MATLAB 2010b2.
Voxel-Based Morphometry (VBM) was performed using
the DARTEL toolbox for SPM (Ashburner and Friston, 2000;
Ashburner, 2007). All default settings were used except where
noted otherwise. Images were aligned into AC/PC orientation
prior to segmenting into gray matter, white matter, and cere-
brospinal fluid. All participants’ gray and white matter images
were then simultaneously registered together to create a study
specific template to reduce between-participant variability. The
1http://www.fil.ion.ucl.ac.uk/spm/software/spm8/
2http://www.mathworks.com/products/matlab/
template was then used to normalize all images into the stan-
dard Montreal Neurological Institute (MNI) space using the
“DARTEL Normalize to MNI Space” program, utilizing the
“preserve amount” option to retain the volumetric data of the
original images. The images were smoothed using a Gaus-
sian kernel with 8 mm full-width half maximum (FWHM).
For statistical analyses, masks for the left and right entorhi-
nal cortex were created from the Juelich Histological Atlas
(Eickhoff et al., 2005). The mean gray matter volumes were
then extracted from the participants MNI aligned gray matter
images with both masks. Lastly, to account for global brain
volume differences, intracranial brain volume for each partic-
ipant was used to normalize extracted gray matter volumes.
Intracranial brain volume was calculated by combining the total
brain volumes found in native space gray matter, white mat-
ter, and cerebrospinal fluid images for each participant. Left
(p = 0.3028, p = 0.5027) and right (p = 0.2231, p = 0.2118)
extracted gray matter volumes for the entorhinal and primary
visual cortex, respectively, were normally distributed according
to the Shapiro-Wilk test; therefore, parametric statistics were
conducted.
RESULTS
GENOTYPING
We isolated and purified DNA from 57 participants to genotype
for two genes associated with increased risk of late onset AD:
APOE and APOJ. The following numbers of subjects per group
were included in analyses: ε2/ε2 (2 subjects), ε2/ε3 (6 subjects),
ε3/ε3 (40 subjects), ε3/ε4 (9 subjects) (Table 1). Because the ε2
allele is associated with a protective effect from AD, analyses were
conducted with and without ε2-carriers. There were two subjects
with the ε2/ε4 genotype, and results from these two subjects were
excluded from all analyses. The distribution of APOE genotypes
was as expected for the United States, with allele frequencies of
0.064 (ε2), 0.783 (ε3), and 0.145 (ε4) (Eisenberg et al., 2010). Of
these subjects, there were 15 APOJ-C/C subjects, 33 APOJ-C/T
subjects, and 9 APOJ-T/T subjects. Both of the excluded subjects
with the APOE-ε2/ε4 genotype also had the APOJ-C/T genotype,
and were excluded from all analyses. The distribution of APOJ
genotypes was also as expected based on previous studies, with
Table 1 | Demographic information.
Genotype Sex Age O.R. Risk
APOE, APOJ score
APOE-ε4/APOJ-C M: 5; F: 3 19.8 ± 1.5 4.3, 1.22 1.657
APOE-ε4/ M: 1; F: 0 19 ± 0 4.3, 1 1.459
APOJ-non-C
APOE-non-ε4/ M: 21; F: 19 21.8 ± 3.5 0.6 or 1, 1.22 0.199
APOJ-C
APOE-non-ε4/ M: 6; F: 2 23.8 ± 6.9 0.6 or 1, 1 0
APOJ-non-C
Values for age represent the mean ± standard deviation. Odds ratios (O.R.) are
normalized to APOE-ε3 and non-APOJ-C, making these values “1”. Risk scores
shown are sums of the natural log of the odds ratios. Non-APOE-ε4 group
includes APOE-ε2 carriers that have O.R. of 0.6.
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FIGURE 1 | Apolipoprotein E -ε4 AD risk genotype is associated with
greater right entorhinal cortex volume. A two-tailed t-test demonstrates
that when participants are grouped based on APOE status alone, the risk
allele (APOE-ε4) is associated with higher right entorhinal cortex volume
compared to the non-risk alleles t(55) = 2.29, p = 0.0259. (*p < 0.05, n = 48
non-APOE-ε4 carriers, n = 9 APOE-ε4 carriers).
FIGURE 2 | Apolipoprotein J-C AD risk genotype is associated
with greater bilateral entorhinal cortex volume, in noncarriers
of APOE -ε4. A two-tailed t-test demonstrates that when
non-APOE-ε4 carriers are grouped based on APOJ status, APOJ-C
carriers have higher left entorhinal cortex volume, t(46) = 2.05,
p = 0.0458, and right entorhinal cortex volume, t(46) = 2.03,
p =0.0485. (*p < 0.05, n = 40 APOJ-C carriers, n = 8 non-APOJ-C
carriers).
allele frequencies of 0.447 (T) and 0.553 (C) (Golenkina et al.,
2010; Table 1).
MRI
To test the hypothesis that the APOE-ε4 and APOJ-C risk
alleles alter the structure of a brain region affected early in
AD pathogenesis (Hyman et al., 1984; Gomez-Isla et al., 1996;
Braak et al., 2011), we extracted gray matter volumetric mea-
surements within the left and right entorhinal cortical regions
of interest for each genotype group. We then conducted a priori
t-tests to interrogate the relationship of each polymorphism with
entorhinal cortex volume. A comparison of APOE-ε4-positive vs.
APOE-ε4-negative individuals, collapsed across APOJ genotype,
revealed significantly greater right entorhinal cortex volume for
APOE-ε4 carriers by 8.47%, t(55) = 2.29, p = 0.0259 (Figure 1,
∗p < 0.05). This effect persisted when APOE-ε2 carriers were
removed from analyses, t(47) = 2.185, p = 0.0339. Differences in
left entorhinal cortex volume in APOE-ε4 carriers compared to
non-carriers did not reach statistical significance, t(55) = 1.261,
p = 0.2126 (Figure 1). To examine the effect of APOJ-C in
the absence of the APOE-ε4 allele, we grouped non-APOE-ε4-
carriers by APOJ-C status (APOJ-C vs. non-APOJ-C-carriers).
This comparison revealed that, among non-APOE-ε4-carriers,
APOJ-C carriers had greater left entorhinal cortex volume by
12.33%, t(46) = 2.05, p = 0.0458, and greater right entorhinal cor-
tex volume by 8.16%, t(46) = 2.03, p = 0.0485 (Figure 2, ∗p< 0.05).
This effect persisted when APOE-ε2 carriers were removed from
analyses for the right entorhinal cortex (t(38) = 2.03, p = 0.0492),
but not the left entorhinal cortex (t(38) = 1.89, p = 0.067).
Based on a putative shared biological pathway, we hypothe-
sized that AD risk factors APOE-ε4 and APOJ-C work together to
alter brain structure in young adults. We explored the possibility
of a combined effect of APOE and APOJ, although the interpreta-
tion is somewhat limited by the small number in one of the groups
(APOE-ε4, APOJ-non-C; Table 1). A t-test of the highest risk
group (APOE-ε4, APOJ-C, n = 8) vs. the lowest risk group (non-
APOE-ε4, non-APOJ-C, n = 6) reveals that greater AD risk is
associated with greater right entorhinal cortex volume by 13.89%,
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FIGURE 3 | Apolipoprotein E and APOJ risk genotypes show an
additive association with greater right entorhinal cortex volume.
A two-tailed t-test shows that when the highest risk group
(APOE-ε4, APOJ-C, n = 8) is compared to the lowest risk group
(non-APOE-ε4, non-APOJ-C, n = 6), greater AD risk is associated
with greater right entorhinal cortex volume by 13.89%, t(12) = 2.27,
p = 0.0421 (*p < 0.05), but not left entorhinal cortex volume,
p > 0.09.
t(12) = 2.27, p = 0.0421, but no difference in left entorhinal cortex
volume, p = 0.09 (Figure 3, ∗p< 0.05). When including APOE-ε2
carriers in the analyses, this effect on the right entorhinal cortex
persists, t(20) = 2.12, p = 0.0464, without changing the effect
on the left entorhinal cortex, p > 0.1. To directly investigate
the combined effect AD risk, we tested whether a “risk score”
variable was predictive of entorhinal cortex volume. Risk score
was weighted by each risk allele’s odds ratio for AD (Bertram et al.,
2007; Carrasquillo et al., 2010; Table 1). Specifically, risk score
was calculated based on APOE and APOJ genotype by combining
the natural log of the odds ratio for each participant to create a
single risk score per participant. Values for the two risk alleles
were added to generate an additive risk score. This risk scores then
served as a regressor for volumetric measurements. The additive
risk score was associated with higher right entorhinal cortex
volume, β = 5.10, F(55) = 5.47, p = 0.023, but not left entorhinal
cortex volume, p > 0.1. This effect persisted as a strong trend
in the absence of the APOE-ε4/non-APOJ-C group, β = 4.36,
F(54) = 3.89, p = 0.0537. As a control measure, we also measured
gray matter volume in one of the last areas affected by AD (pri-
mary visual cortex, V1). As anticipated, neither left (β = 0.3313,
p = 0.9117) nor right (β = −0.6976, p = 0.8168) V1 volumes
were correlated with risk score. Moreover, no APOE-genotype
associated differences were observed in the left (p = 0.8115) or
right (p = 0.8446) V1. Overall, these results suggest the possibility
that AD risk-related genes APOE and APOJ additively affect brain
volume in young people within the entorhinal cortex.
DISCUSSION
Apolipoprotein E is the strongest genetic risk factor for AD, and
the entorhinal cortex is one of the earliest brain regions to develop
neuropathological lesions and atrophy in AD (Hyman et al., 1984;
Gomez-Isla et al., 1996; Braak et al., 2011). Because pathogenesis
of AD begins as early as two decades prior to the presentation
of clinical symptoms (Bateman et al., 2012), it is plausible that
a series of genetically-induced differences in brain structure—
such as entorhinal cortex volume—could accumulate with aging
to increase vulnerability to AD later in life. Here, we assayed
entorhinal cortex volume in a cohort of young adults to directly
investigate whether APOE and APOJ genetic AD risk alters the
structure of this region in early adulthood. Apolipoprotein E-ε4
carriers exhibited greater entorhinal cortex volume in the right
hemisphere (Figure 1), and further analysis revealed that the
APOJ-C genotype was associated with higher bilateral entorhinal
cortex volume in APOE-ε4 non-carriers (Figure 2). The highest
risk group (APOE-ε4, APOJ-C) exhibited greater entorhinal cor-
tex volume compared to the lowest risk group (non-APOE-ε4,
non-APOJ-C) (Figure 3). When additive odds ratios of APOE and
APOJ served as regressors for volumetric measurements, higher
disease risk was associated with greater right entorhinal cortex
volume.
Volumetric studies report conflicting results when examining
MTL volume in APOE risk carriers depending on the experimen-
tal parameters. For instance, one study of infants 1–3 months
old with family histories of schizophrenia found APOE-associated
differences in temporal lobe volume, including the hippocampus
and entorhinal cortex (Knickmeyer et al., 2013). However, this
effect was not seen in a follow up study with 6–25 month old
infants with no family history of schizophrenia (Dean et al.,
2014). Similarly, while some evidence has suggested that healthy
APOE-ε4 positive adults exhibit decreased bilateral hippocampal
volume (O’dwyer et al., 2012) and gray matter density in the
right medial temporal region (Wishart et al., 2006), another
study in young adults reported that APOE-ε4 carriers showed
relative increases in volume in the vicinity of the hippocampus
(Alexander et al., 2012). Further contributing to the controversy,
other studies have suggested no differences in MTL volume by
APOE genotype (Mondadori et al., 2007; Filippini et al., 2009;
Dennis et al., 2010; Samuraki et al., 2012; Stein et al., 2012;
Matura et al., 2014). Less research has focused on the lesser AD
risk factor, APOJ, and its effect on MTL volume. The limited
extant research has suggested no difference exists in the MTL by
APOJ genotype (Bralten et al., 2011; Stein et al., 2012). A meta-
analysis of GWAS including over 7000 cognitively normal subjects
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showed that APOJ genotype was not significantly associated with
hippocampal volume (Stein et al., 2012). However, this study
did not focus on young adults or target the entorhinal cortex
specifically. While the APOJ-C risk allele has no significant effect
on gray matter volume by whole brain analyses in young adults,
a related risk gene, CR1, was associated with smaller local gray
matter volume in the entorhinal cortex in a prior study (Bralten
et al., 2011).
The inconsistency of extant evidence could be due to dif-
ferences in age, gender, exclusion criteria, statistical methods,
family history, and how each region of interest was defined across
studies. Another explanation may be that the entorhinal cortex is a
relatively small region within the MTL, and few studies explicitly
target the entorhinal cortex. Thus, it is possible that changes in
entorhinal cortex volume are not large enough to alter volume of
the MTL as a whole. By specifically targeting the entorhinal cortex
in our study, we were able to detect differences in this relatively
small MTL structure that may have otherwise been below the
threshold for detection.
Our results indicate that the effects of APOE and APOJ may
be stronger in the right hemisphere. Medial temporal lobe asym-
metry has been linked with AD and disease progression. For
instance, APOE-ε4 carriers have thinner left entorhinal cortex
compared to the right, while those without APOE-ε4 show this
asymmetry in the presence of AD pathology (Donix et al., 2013).
Individuals with subjective memory impairment had reduced
volumes of the hippocampus and entorhinal cortex bilaterally
(Striepens et al., 2010). However, APOE-ε4 carriers without this
impairment performed better on episodic memory tests and had
larger right hippocampal volumes, as opposed to those with
impairment performing worse with smaller right hippocampal
volumes (Striepens et al., 2011). Interestingly, differences in sym-
metry were also reported in delusional AD patients with greater
right temporal horn sizes than left, while non-delusional patients
did not show this asymmetry (Geroldi et al., 2000). Although
asymmetry effects have not yet reported for APOJ, it is possi-
ble that APOE may work in conjunction with APOJ to induce
asymmetry.
With aging, reductions in MTL volume in the hippocampus
and entorhinal cortex are correlated with cognitive decline in
the elderly (Bergfield et al., 2010; Raz et al., 2010; Varon et al.,
2011). However, reductions in gray matter volume during the
course of brain development in adolescence and early adulthood,
correlate with increased synaptic pruning (Gogtay et al., 2004).
Thus, increased entorhinal cortex volume during this develop-
mental window could indicate a deficit in neural efficiency. Our
study involved individuals of an average age of 21.8 years old,
all of whom are at these later stages of brain development. Prior
evidence has linked the APOJ-C risk allele to abnormal brain
development through decreased white matter integrity (Braskie
et al., 2011) and subsequent altered coupling between the hip-
pocampus and prefrontal cortex during memory processing, mir-
roring disrupted connectivity in patients (Erk et al., 2011). Other
evidence has also linked APOE-ε4 to abnormal brain structural
and functional development in young risk allele carriers, suggest-
ing that APOE and APOJ risk may impede the pruning process in
the entorhinal cortex.
Alternatively, these findings could contribute to evidence sug-
gesting that the APOE and APOJ risk genes confer an evolutionary
advantage early in life, but confer a disadvantage later in life by
increasing AD risk. This antagonistic pleiotropy hypothesis of
APOE and APOJ risk has been proposed in other contexts (e.g.,
see Tuminello and Han, 2011; Stevens et al., 2014). College-aged
young adults carrying the APOE-ε4 allele have an advantage in
verbal fluency, decision making, and memory (Zetterberg et al.,
2009; Marchant et al., 2010; Jochemsen et al., 2012; Rusted et al.,
2013; Green et al., 2014), but these advantages disappear by mid-
dle age and give way to impairment in old age. These beneficial
effects early in life could be due in part to increased volume in
the entorhinal cortex, allowing for more effective processing of
memory-associated information.
Finally, larger entorhinal cortex volume in APOE and APOJ
risk carriers could indicate more neuroinflammation in the
entorhinal cortex of young adults. It has been postulated that
APOE-ε4 may increase neuroinflammation during aging, thus
increasing susceptibility to dementia later in life (e.g., for review,
see Guo et al., 2004; Kim et al., 2009). Several studies have also
linked APOJ-C risk to decreased CLU levels (Schurmann et al.,
2011), which are thought to serve an anti-inflammatory role
(Savkovic et al., 2007). Glia can contribute to half of brain volume
changes (Snell, 2009), and studies have shown that APOE-ε4 is
associated with increased neuroinflammation (Guo et al., 2004;
Chen et al., 2005; Maezawa et al., 2006; Zhu et al., 2012). Because
the entorhinal cortex is one of the earliest affected brain areas in
AD, it is possible that the increase in entorhinal cortex volume
could be due to a deficit in APOE and APOJ carriers to control
neuroinflammation in the young adult brain.
Overall, our findings in a young adult cohort indicate an
additive effect of two of the strongest AD risk factors on a brain
locus at the epicenter of AD pathogenesis. Entorhinal cortex
volume increased as a function of increasing APOE and APOJ
genetic AD risk. These results contribute to a growing literature
characterizing genetic markers of AD risk in the young brain, long
before the first overt signals of Alzheimer’s appear. Thus, these
findings inform our understanding of the role of these genetic risk
factors in the normal brain, and contribute to the development of
biomarker targets for future preventive AD therapies.
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